Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Biocon confirms US Neulasta rival launch

Executive Summary

Biocon has confirmed that the company’s Fulphila (pegfilgrastimjmdb) biosimilar has been launched by partner Mylan in the US, at a 33% discount to reference product Neulasta’s wholesale acquisition cost (WAC).

You may also be interested in...



Mylan And Biocon Introduce Fulphila In Australia

Mylan and Biocon have launched their Fulphila biosimilar version of pegfilgrastim in Australia, marking the pair’s third local biosimilar launch under their partnership.

Pfizer To Merge Off-Patent Business With Mylan

Pfizer has announced plans to merge its off-patent unit with Mylan, creating a new generics and biosimilars giant in the US.

Wait For Strategic Decisions Weighs Heavily On Mylan

With no news on the progress of a board-level strategic review on offer, investors reacted negatively to Mylan falling short of consensus sales figures. This took the firm's share price to its lowest level for more than five years.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

GB001049

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel